(MYGN) Myriad Genetics, Inc. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYGN) Myriad Genetics, Inc. Complete Analysis Pack
Myriad Genetics VRIO: See Its Real Strengths and Strategic Weaknesses
Unlock where Myriad Genetics, Inc. really wins—and where it’s vulnerable—with the full VRIO Analysis. This concise, downloadable report maps value, rarity, imitability, and organization for each key resource, giving analysts and investors a clear, actionable view of sustainable advantages and strategic gaps.
BRACAnalysis CDx hereditary cancer franchise
Value
BRACAnalysis CDx is a key companion test for BRCA1/2-mutated breast, ovarian, pancreatic, and prostate cancers, where BRCA mutations drive about 5%-10% of breast and 10%-15% of ovarian cases. Its clear therapy impact helps support reimbursement and physician use.
Rarity
Multigene panels are common, but BRACAnalysis CDx is rarer because it has about 30 years of BRCA clinical data, starting in 1996. That long evidence base, plus FDA-cleared companion-diagnostic use, gives Myriad Genetics a harder-to-copy proof set than newer panel tests.
Imitability
BRACAnalysis CDx is only moderately imitable because rivals must still prove analytical validity, secure FDA/CMS alignment, and build clinical utility data. Myriad Genetics reported full-year 2025 revenue of about $787 million, with hereditary cancer testing as a core driver, showing the franchise’s scale and the evidence bar competitors must clear.
Organization
Myriad Genetics, Inc. uses established oncology and women’s health channels to keep BRACAnalysis CDx in front of physicians, payers, and genetic counselors, which supports repeat ordering and reimbursement access. That channel reach matters in hereditary cancer, where testing volume stays high and Myriad’s FY2025 business still leaned on this franchise as a core part of its roughly $700 million-plus revenue base.
Competitive Advantage
BRACAnalysis CDx has a temporary edge because it is one of the best-known BRCA companion diagnostics, with strong physician recognition and payer access built over years. But that advantage is not durable: broader multigene panels and faster, cheaper rivals keep pressuring Myriad Genetics, Inc. hereditary cancer share in fiscal 2025.
Myriad’s BRACAnalysis CDx Remains a Durable Growth Engine
BRACAnalysis CDx remains a sticky hereditary cancer franchise for Myriad Genetics, Inc. because its BRCA1/2 evidence base, FDA-cleared companion-diagnostic role, and payer familiarity are hard to copy. In FY2025, Myriad Genetics, Inc. reported about $787 million in revenue, with hereditary cancer testing still a core driver.
| Metric | FY2025 |
|---|---|
| Myriad Genetics, Inc. revenue | About $787 million |
| BRCA-linked breast cancer share | About 5%-10% |
| BRCA-linked ovarian cancer share | About 10%-15% |
| Clinical evidence base | About 30 years |
What is included in the product
Detailed Word Document
Evaluates Myriad Genetics’ key resources and capabilities to determine which are valuable, rare, hard to imitate, and well organized.
Customizable Excel Spreadsheet
Quickly shows which Myriad Genetics resources are valuable, rare, and hard to copy, revealing real competitive advantage and defensibility.
Reference Sources
Clarifies which Myriad resources truly yield sustainable advantage by testing value, rarity, imitability, and organizational support.
MyRisk hereditary cancer testing and interpretation
Value
MyRisk hereditary cancer testing has high Value because BRCA results can change treatment choices in breast, ovarian, pancreatic, and prostate cancers, including PARP inhibitor use and surgery planning. BRCA1/2 carriers face much higher lifetime cancer risk, and Myriad’s long track record and guideline-backed clinical utility support payer reimbursement and physician adoption.
Rarity
Multigene panels are now common in hereditary cancer testing, but Myriad Genetics, Inc. has a rarer asset: a long clinical evidence base behind MyRisk hereditary cancer testing and interpretation. That history matters because variant calls, risk estimates, and care guidance are backed by years of real-world data, not just the size of the panel.
Imitability
Imitability is moderate because a rival can build a hereditary cancer panel, but matching Myriad Genetics, Inc.’s MyRisk requires years of validation, regulatory alignment, and payer-backed clinical utility evidence. That moat is harder to copy than the test itself, especially after 20+ years of evidence building in this category.
Organization
MyRisk hereditary cancer testing is a 48-gene panel, and Myriad Genetics, Inc. sells it through established oncology and women’s health channels. That channel reach is a real VRIO edge: it is hard to copy fast, and it helps Myriad keep clinical adoption high.
Competitive Advantage
MyRisk hereditary cancer testing and interpretation gives Myriad Genetics, Inc. a temporary competitive advantage because it combines a 48-gene panel with a large variant database and clinician support, which helps labs deliver faster, more actionable risk calls. The edge is real but not permanent: hereditary cancer testing is crowded, and rivals can copy panel breadth and interpretation tools over time.
MyRisk’s 48 Genes, 20+ Years of Data: A Hard-to-Copy Edge
MyRisk hereditary cancer testing remains valuable because a 48-gene panel plus interpretation can change surgery, surveillance, and PARP inhibitor decisions, especially for BRCA1/2. Myriad Genetics, Inc.’s edge is the evidence base: more than 20 years of variant and outcomes data makes its risk calls harder to copy than the panel itself.
| Metric | Data |
|---|---|
| Panel size | 48 genes |
| Clinical moat | 20+ years |
What You See Is What You Get
VRIO Analysis
The document you're previewing is the actual Myriad Genetics, Inc. VRIO Analysis—not a mockup or sample—and it reflects the exact structure, content, and insights you’ll receive after purchase.
When you complete your order, you’ll instantly download this same professional file in editable Word and Excel formats, fully formatted and ready to present or customize.
No placeholders, no condensed excerpts—what you see here is a live section of the final deliverable; the purchased file contains the complete VRIO Analysis with all pages and data included.
MyChoice CDx HRD companion diagnostic
Value
MyChoice CDx HRD has strong value because it helps guide PARP inhibitor use in BRCA-mutated breast, ovarian, pancreatic, and prostate cancers. That direct link to therapy choice gives it clear clinical utility, which supports reimbursement and makes physicians more likely to adopt it.
Rarity
Multigene panels are common, but Myriad Genetics, Inc. stands out because MyChoice CDx has a longer HRD evidence base and FDA companion-diagnostic use in ovarian cancer since 2016, so the test is not easy to copy. That history matters in a market where many labs can run panels, but far fewer can match years of validated clinical data and payer trust.
Imitability
Imitability is moderate for MyChoice CDx HRD companion diagnostic because rivals can copy the test format, but they still need analytical validation, regulatory alignment, and clinical utility evidence across each drug label. That evidence barrier is real: Myriad Genetics, Inc. keeps a protected CDx position by tying the test to approved PARP inhibitor use and years of trial-backed data, not just the assay itself.
Organization
Myriad sells MyChoice CDx HRD through its established oncology and women’s health channels, so it can reach the same clinicians and labs without building a new sales network. That channel depth helps protect a hard-to-copy asset: an FDA-approved companion diagnostic that sits inside Myriad’s 2025 commercial base.
Competitive Advantage
MyChoice CDx HRD companion diagnostic gives Myriad Genetics, Inc. a temporary competitive advantage because it is an established, FDA-backed test tied to PARP inhibitor use, and the HRD market still has limited direct substitutes. That edge is not lasting: pricing pressure and new tumor-agnostic or lab-developed tests can narrow the moat fast, especially as Myriad Genetics, Inc. keeps competing in a market where 2025 R&D spending stayed near the low-$100 million range.
MyChoice CDx HRD Gives Myriad a Durable, Evidence-Backed Edge
MyChoice CDx HRD gives Myriad Genetics, Inc. a real moat because it is tied to PARP inhibitor use and has FDA companion-diagnostic status in ovarian cancer since 2016. Copying the assay is possible, but matching its clinical evidence, payer trust, and channel reach is harder. In 2025, Myriad Genetics, Inc. kept R&D near the low-$100 million range, which still supports the asset but does not make the edge permanent.
| Factor | Signal |
|---|---|
| FDA CDx status | Since 2016 |
| R&D spend | Near low-$100M in 2025 |
| Moat | Moderate, evidence-led |
Prolaris and EndoPredict prognostic platforms
Value
Prolaris and EndoPredict add value because they guide treatment intensity in breast and prostate cancer, and Myriad Genetics links that clinical use to payer coverage and physician adoption. Prolaris uses a 46-gene cell-cycle score, while EndoPredict uses an 8-gene score plus clinical factors to refine recurrence risk and support more precise decisions.
Rarity
Multigene panels are common, but Myriad Genetics, Inc.'s Prolaris and EndoPredict stand out because their prognostic claims rest on a much longer clinical evidence trail, not just the gene count. That is rarer in a crowded market where many assays can measure risk, but fewer have years of published validation and guideline uptake.
Imitability
Prolaris and EndoPredict are only moderately easy to copy. A rival would need broad clinical validation, regulatory alignment, and payer-ready clinical utility data; that evidence stack is hard and costly to build, and Myriad Genetics still benefits from long-running physician and reimbursement trust.
Organization
Myriad Genetics, Inc. sells Prolaris and EndoPredict through established oncology and women’s health channels, which lowers go-to-market friction and supports repeat ordering. In VRIO terms, that channel reach is valuable and hard to copy because it sits inside long-term clinician and lab relationships.
Competitive Advantage
Prolaris and EndoPredict give Myriad Genetics, Inc. a temporary competitive advantage because they are clinically useful prognostic tests, but that edge is narrow and can fade as rivals expand validation and reimbursement. In FY2025, the key test is whether their evidence and payer access can keep pace with a market where differentiation is mostly clinical, not structural.
Prolaris and EndoPredict: Strong, Hard-to-Copy Oncology Tests
Prolaris and EndoPredict are clinically useful and hard to copy because they combine gene-expression risk scores with long validation histories, payer access, and oncology channel reach. Prolaris uses a 46-gene score; EndoPredict uses an 8-gene score plus clinical factors, giving Myriad Genetics, Inc. a defensible but not unassailable edge.
| Platform | Core signal | VRIO take |
|---|---|---|
| Prolaris | 46-gene score | Useful, evidence-backed |
| EndoPredict | 8-gene plus clinical factors | Useful, harder to copy |
GeneSight psychotropic pharmacogenomic test
Value
GeneSight’s value is its ability to flag gene-drug mismatches before prescribing, which can cut trial-and-error in antidepressant care and support payer coverage. Myriad Genetics, Inc. says the test is backed by clinical studies and used by payers and physicians because it helps guide treatment faster, with mental illness affecting about 1 in 5 U.S. adults each year.
Rarity
Rarity is moderate: multigene pharmacogenomic panels are common, but Myriad Genetics, Inc.’s GeneSight stands out because it has one of the longer clinical evidence tracks in the category, with multiple published studies over more than 10 years. That depth matters in a market where many tests can match the panel format, but fewer can match the evidence base.
Imitability
GeneSight’s imitability is moderate because rivals can copy the test design, but they still need validation, regulatory alignment, and proof of clinical utility. That evidence barrier matters in psychiatry, where Myriad Genetics, Inc. has spent years building real-world data and payer acceptance.
Organization
Myriad Genetics, Inc. uses 2 established commercial channels, oncology and women’s health, to sell GeneSight psychotropic pharmacogenomic test, which lowers go-to-market cost and speeds access to prescribers. That organization is valuable and hard to copy because it is already embedded in Myriad Genetics, Inc.’s lab-sales and payer workflows.
Competitive Advantage
GeneSight psychotropic pharmacogenomic test gives Myriad Genetics, Inc. a temporary edge because it turns a 3-gene panel into prescribing guidance for more than 60 psychiatric drugs, which can help doctors avoid trial-and-error starts. But the edge is not durable: other pharmacogenomic tests can match the core science, and payer coverage can shift fast.
GeneSight’s Evidence-Backed Edge in Psychiatry
GeneSight has strong value in psychiatry because it helps avoid gene-drug mismatches across 60+ psychotropic drugs, and Myriad Genetics, Inc. says it is backed by published studies and payer use. Rarity is moderate, but the evidence base is a real barrier, especially with U.S. mental illness affecting about 1 in 5 adults each year.
| Factor | Data |
|---|---|
| Drug coverage | 60+ |
| U.S. adult impact | 1 in 5 |
| Evidence moat | 10+ years |
Prenatal and carrier screening platform
Value
Myriad Genetics, Inc.'s prenatal and carrier screening platform has clear value because its BRCA-related testing helps guide treatment in four major cancers: breast, ovarian, pancreatic, and prostate. Strong clinical utility supports payer reimbursement and physician use, which is why this platform stays central to adoption.
Rarity
Multigene panels are common in prenatal and carrier screening, but Myriad Genetics, Inc.'s long clinical evidence base is less common. That depth comes from decades of test data and published studies, which can make the platform harder to copy than a standard panel menu.
Imitability
Imitability is moderate: rivals can build a similar prenatal and carrier screen menu, but they still need years of validation, payer support, and regulatory alignment. Myriad Genetics, Inc.'s Foresight Carrier Screen covers 175+ conditions, and that clinical evidence base is hard to copy fast.
Organization
Myriad Genetics, Inc. has the Organization to capture value here: it sells prenatal and carrier screening through its established oncology and women’s health channels, which lowers go-to-market costs and speeds adoption. That channel reach is a real edge because screening demand is recurring and tied to clinician ordering, so the platform is harder for smaller rivals to match.
Competitive Advantage
Myriad Genetics, Inc.'s prenatal and carrier screening platform has a temporary edge: it has strong brand trust and broad test menus, but rivals keep narrowing the gap and payer pressure limits pricing power. In Myriad Genetics, Inc.'s latest reported year, this business still mattered, but its moat is not durable because test differentiation can be copied fast.
Myriad’s Foresight Screen Still Holds a Durable Moat
Myriad Genetics, Inc.'s prenatal and carrier screening platform still has value because Foresight Carrier Screen covers 175+ conditions and benefits from long clinical validation. That evidence base, plus payer and clinician trust, makes the platform harder to copy than a standard panel.
| Metric | Detail |
|---|---|
| Foresight Carrier Screen | 175+ conditions |
| Moat | Clinical evidence and payer support |
Proprietary genomic and clinical data asset
Value
Myriad Genetics, Inc.'s proprietary genomic and clinical data asset helps guide therapy choices across 4 BRCA-linked cancers: breast, ovarian, pancreatic, and prostate. Its strong clinical utility supports payer reimbursement and physician adoption, which helps protect the value of a data set built from millions of test results and linked outcomes.
Rarity
Multigene panels are common, but Myriad Genetics, Inc.’s long clinical evidence base is rarer. The Company has built 25+ years of hereditary cancer testing and millions of patient results, which gives its reports more real-world context than a typical panel. That depth is hard for newer labs to copy quickly.
Imitability
Imitability is moderate because rivals cannot quickly copy Myriad Genetics, Inc.'s proprietary genomic and clinical data; they need validation, regulatory alignment, and proof of clinical utility. That takes years of evidence-building, so the barrier is real, even if not absolute.
Myriad Genetics, Inc. still faces copy pressure from big data players, but the moat holds while its database keeps growing and its tests stay tied to clinical outcomes. The key hurdle is not data collection alone; it is gaining physician trust and payer acceptance through repeatable evidence.
Organization
Myriad Genetics’ proprietary genomic and clinical data asset is valuable because it improves test interpretation and strengthens its established oncology and women’s health sales channels. The company can use that data to support payer discussions, guide provider adoption, and reinforce repeat testing demand, which is hard for smaller rivals to copy.
Competitive Advantage
Myriad Genetics, Inc. has built a proprietary genomic and clinical data asset from more than 5 million tested patients, which helps refine variant interpretation and risk scores. That data scale is hard to copy fast, but rivals can narrow the gap through partnerships and fresh sequencing, so the edge is temporary.
Myriad’s 25-Year Data Moat Still Powers Its Oncology Edge
Myriad Genetics, Inc.'s proprietary genomic and clinical data asset remains hard to copy because it combines 25+ years of hereditary cancer evidence with more than 5 million tested patients. That depth supports variant interpretation, payer talks, and physician trust, which keeps its oncology testing moat relevant.
| Metric | Data |
|---|---|
| Tested patients | 5M+ |
| Evidence base | 25+ years |
| Covered cancers | 4 BRCA-linked |
Strategic partnerships and ecosystem access
Value
Myriad Genetics, Inc. uses strategic partnerships and ecosystem access to steer therapy in BRCA-mutated breast, ovarian, pancreatic, and prostate cancers. With BRCA variants found in about 5% to 10% of breast and 10% to 15% of ovarian cancers, its strong clinical utility helps support payer reimbursement and physician adoption.
Rarity
Multigene panels are now common across oncology, but Myriad Genetics, Inc. stands out because it has built more than 25 years of clinical evidence behind its hereditary cancer tests. That long record, including early BRCA testing and large real-world datasets, makes its ecosystem access harder to copy than the panel itself.
Imitability
Imitability is moderate because rivals can copy strategic partnerships, but only after they secure clinical validation, regulatory alignment, and proof of clinical utility. Myriad Genetics, Inc. has built ecosystem access through long-running lab and payer ties, and those trust links are harder to replicate than the deals themselves.
Organization
Myriad Genetics is organized to sell through established oncology and women’s health channels, which gives it direct access to clinicians and payer workflows and makes its test menu easier to place at scale. That channel reach is valuable and hard to copy quickly because it depends on long-standing lab, sales, and referral relationships across two core markets.
Competitive Advantage
In 2025, Myriad Genetics, Inc. uses payer, provider, and pharma partnerships to widen access to its tests and boost referral flow, but these links are easier for rivals to copy than its core assay IP. That makes the edge a temporary competitive advantage, not a durable moat.
Partnerships Expand Reach, But Evidence Is the Real Moat
Myriad Genetics, Inc.'s partnerships with payers, providers, and pharma expand access to hereditary cancer testing, but they do not create a strong moat. The edge comes from long-running clinical evidence and workflow ties, not the partnerships themselves, so rivals can copy the channel strategy over time.
| Item | Data |
|---|---|
| Clinical evidence base | 25+ years |
| BRCA-linked breast cancer | 5% to 10% |
| BRCA-linked ovarian cancer | 10% to 15% |
Regulated lab operations and commercialization know-how
Value
Myriad Genetics, Inc. uses regulated lab operations and commercialization know-how to turn BRCA results into treatment choices across breast, ovarian, pancreatic, and prostate cancers; BRCA1/2 testing is a core input for PARP inhibitor use and surgery planning. Strong clinical utility helps support reimbursement and physician adoption, which lowers sales friction.
Rarity
Multigene panels are common, but Myriad Genetics, Inc. is rarer because it pairs them with over 20 years of clinical evidence from BRACAnalysis and myRisk, plus a 48-gene hereditary cancer panel. That evidence depth supports payer trust and physician use, which is harder to copy than the test format itself.
Imitability
Imitability is moderate because Myriad Genetics’ regulated lab operations and commercialization know-how take time to copy: rivals need clinical validation, regulatory alignment, and proof of clinical utility before payers and doctors trust the tests. That barrier is stronger than pure software, since each assay must clear evidence and compliance gates before it can scale.
Organization
Myriad Genetics runs regulated lab operations through CLIA and CAP-accredited sites, and it sells tests through established oncology and women’s health channels. In FY2024, it generated about $840 million in revenue and ended the year with roughly $200 million in cash and short-term investments, which shows the scale behind that commercialization setup.
Competitive Advantage
Myriad Genetics, Inc. has a temporary competitive advantage here because its CLIA-regulated lab network and reimbursement know-how speed test launch and payer access, but these skills are easier to copy than patents. In FY2025, it still faced margin pressure, with revenue near $800 million and the business leaning on scale and compliance discipline to protect share.
Myriad’s Reimbursement Edge Still Sets It Apart
Myriad Genetics, Inc. keeps a durable edge here because CLIA and CAP lab discipline plus payer-facing sales know-how make its BRCA and multigene tests easier to launch, reimburse, and use in care. FY2025 revenue was about $800 million, after about $840 million in FY2024, showing a scaled but still pressured model.
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenue | $840M | ~$800M |
| Core moat | Regulated lab ops and payer access | |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.